Загрузка...
A 10-year follow-up of infliximab monotherapy for refractory uveitis in Behçet’s syndrome
Infliximab (IFX) was the first biologic introduced for refractory uveitis treatment in Behçet’s syndrome (BS). However, there have been few reports on the safety and efficacy of IFX monotherapy over follow-up periods of more than 10 years. This retrospective study evaluated the 10-year safety and ef...
Сохранить в:
| Опубликовано в: : | Sci Rep |
|---|---|
| Главные авторы: | , , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Nature Publishing Group UK
2020
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7747559/ https://ncbi.nlm.nih.gov/pubmed/33335139 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41598-020-78718-z |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|